Cara Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2004-07-02

Employees: 55

Market Cap: $19.6M

Website: http://www.caratherapeutics.com

Introduction: CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Clinical Trials

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Phase 2

Terminated

Conditions: Cholestatic Pruritus

Interventions: Drug: CR845 1.0 mg
Drug: Placebo

First Posted Date: 2019-06-21

Last Posted Date: 2023-07-03

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 14

Registration Number: NCT03995212

Locations: 🇺🇸
Cara Therapeutics Study Site, Morgantown, West Virginia, United States
🇺🇸
Cara Therapeutics Study Site 2, Boston, Massachusetts, United States

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Hemodialysis

Interventions: Drug: [14C] CR845

First Posted Date: 2019-05-13

Last Posted Date: 2019-07-24

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 12

Registration Number: NCT03947970

Locations: 🇺🇸
Cara Therapeutics Study Site, San Antonio, Texas, United States

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Phase 3

Completed

Conditions: Uremic Pruritus

Interventions: Drug: Placebo
Drug: CR845 0.5 mcg/kg

First Posted Date: 2018-08-17

Last Posted Date: 2022-04-26

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 473

Registration Number: NCT03636269

Locations: 🇬🇧
Cara Therapeutics Study Site, Westcliff-on-Sea, United Kingdom
🇰🇷
Cara Therapeutics Study Site 3, Seoul, Korea, Republic of
🇨🇳
Cara Therapeutics Study Site 2, Taipei, Taiwan

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Phase 2

Completed

Conditions: Chronic Kidney Diseases
Pruritus

Interventions: Drug: Placebo Oral Tablet
Drug: CR845 0.25 mg Oral Tablet
Drug: CR845 0.5 mg Oral Tablet
Drug: CR845 1 mg Oral Tablet

First Posted Date: 2018-08-06

Last Posted Date: 2024-01-24

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 269

Registration Number: NCT03617536

Locations: 🇺🇸
Cara Therapeutics Study Site 1, Miami, Florida, United States
🇺🇸
Cara Therapeutics Study Site 2, Flint, Michigan, United States
🇺🇸
Cara Therapeutics Study Site, Alexandria, Virginia, United States

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Phase 3

Completed

Conditions: Uremic Pruritus

Interventions: Drug: Placebo
Drug: CR845 0.5 mcg/kg

First Posted Date: 2018-02-06

Last Posted Date: 2022-04-26

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 378

Registration Number: NCT03422653

Locations: 🇺🇸
Cara Therapeutics Study Site 2, Beverly Hills, California, United States
🇺🇸
Cara Therapeutics Study Site, Wauwatosa, Wisconsin, United States
🇺🇸
Cara Therapeutics, La Mesa, California, United States

and more 1 locations

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Phase 3

Completed

Conditions: Uremic Pruritus

Interventions: Drug: CR845

First Posted Date: 2017-09-13

Last Posted Date: 2021-10-14

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 288

Registration Number: NCT03281538

Locations: 🇵🇷
Cara Therapeutics Study Site, San Juan, Puerto Rico

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Phase 2

Completed

Conditions: Osteoarthritis, Hip
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

Interventions: Drug: CR845 tablet 1 mg
Drug: CR845 tablet 2.5 mg
Drug: CR845 tablet 5 mg
Drug: Placebo tablet

First Posted Date: 2016-10-25

Last Posted Date: 2020-10-20

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 761

Registration Number: NCT02944448

Locations: 🇺🇸
Cara Therapeutics Study Site, Charlottesville, Virginia, United States

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Phase 2

Completed

Conditions: Uremic Pruritus

Interventions: Drug: CR845 1 mcg/kg
Drug: Placebo
Drug: CR845 0.5 mcg/kg
Drug: CR845 1.5mcg/kg

First Posted Date: 2016-08-08

Last Posted Date: 2020-07-29

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 226

Registration Number: NCT02858726

Locations: 🇺🇸
Cara Therapeutics Investigator Site, Philadelphia, Pennsylvania, United States
🇺🇸
Cara Therapetics Study Site, Knoxville, Tennessee, United States
🇺🇸
Cara Therapeutics Study Site, Milwaukee, Wisconsin, United States

and more 1 locations

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Phase 2

Completed

Conditions: Post Abdominal Surgery Pain

Interventions: Drug: CR845 IV 1 mcg/kg
Drug: CR845 IV 0.5 mcg/kg
Drug: Placebo IV

First Posted Date: 2015-09-07

Last Posted Date: 2019-05-31

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 451

Registration Number: NCT02542384

Locations: 🇺🇸
Cara Therapeutics Study Site, Salt Lake City, Utah, United States

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: CR845 5 mg
Drug: CR845 0.25 mg
Drug: CR845 0.50 mg
Drug: CR845 1 mg

First Posted Date: 2015-08-14

Last Posted Date: 2017-01-31

Lead Sponsor: Cara Therapeutics, Inc.

Target Recruit Count: 81

Registration Number: NCT02524197

Locations: 🇺🇸
Triad Clinical Trials, LLC, Greensboro, North Carolina, United States
🇺🇸
Clinical Investgations of Texas, Plano, Texas, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 2 locations

Home Terms & Conditions Privacy Policy